ArticleBMC microbiology2025
Whole-genome sequencing and genomic characterization of a novel multi-drug resistant esxA-positive Staphylococcus haemolyticus DUEML1 (ST-184) isolated from a respiratory infection case: insights from panresistome analysis.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStaphylococcus haemolyticus is a coagulase-negative staphylococcal species and an opportunistic pathogen associated with hospital-acquired infections. The aim of this study was to use whole-genome sequencing (WGS) to characterize a novel multidrug-resistant (MDR) S. haemolyticus strain, DUEML1 (ST-184), isolated from a respiratory infection case in Bangladesh, and to place its resistome and virulence features in the context of global S. haemolyticus isolates.
methodsThe isolate was obtained in pure culture from the tracheal aspirate of a 51-year-old male patient with respiratory infection, suggesting it was the primary causative agent. WGS was the primary method to analyze the genome of the isolated strain and subsequent in-silico analyses were performed to identify antimicrobial resistance genes, virulence factors, plasmid-associated genes, mobile genetic elements (MGEs), and prophages. Comparative pan-resistome analysis was conducted using 694 publicly available S. haemolyticus genomes retrieved from NCBI.
resultsThe isolate exhibited in vitro resistance to levofloxacin, ciprofloxacin, tetracycline, doxycycline, gentamicin, and trimethoprim-sulfamethoxazole, as determined by the disc diffusion test, and demonstrated the capacity for biofilm formation. Several antimicrobial resistance genes (ARGs) such as fosBx1, mgrA, norC, sdrM, sepA and two virulence genes, including esxA and cap8G were detected. To our knowledge, this is the first report of an esxA-positive S. haemolyticus isolate, recovered from a respiratory infection case in Dhaka, Bangladesh. Two plasmid-associated genes repUS23 and repUS46 were detected. Further analyses predicted 63 horizontal gene transfer (HGT) events and identified 147 MGEs, including integration/excision elements, recombination and repair-associated genes, and prophage-associated regions. With a new variant of arcC allele (arcC-38), the isolate was assigned to a novel ST-184. The PathogenFinder predicted a 93% probability that ST-184 is a human pathogen. A comparative analysis of 694 genome sequences identified a wide variety of ARGs, virulence factors, and plasmids in S. haemolyticus isolates from 35 different countries.
conclusionThis study provides the first genomic characterization of a novel S. haemolyticus ST-184 isolate from Bangladesh, highlighting its multidrug-resistant nature and virulence potential. A limitation of this work is the lack of clinical treatment outcome data. Future research should include large-scale genomic surveillance to strengthen our understanding of the genomic architecture of S. haemolyticus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.